H5N1 Bird Flu Vaccine Approved
MONDAY, Nov. 25, 2013 (HealthDay News) -- A new vaccine has been approved by the U.S. Food and Drug Administration to prevent the so-called "bird flu" virus in adults at greater-than-average risk of exposure, the FDA said.
While most strains of bird flu don't infect people, the H5N1 virus has caused "serious illness and death in people outside of the U.S., mostly among people who have been in close contact with infected and ill poultry," the agency said in a news release announcing the approval.
The shot, called the Influenza A (H5N1) Virus Monovalent Vaccine, has been developed "in the event that the H5N1 avian influenza virus develops the capability to spread efficiently from human to human, resulting in the rapid spread of the disease across the globe," the FDA added.
The vaccine, produced by a Canadian subsidiary of GlaxoSmithKline, is not intended for commercial distribution, the FDA said. It's designed to be administered in two doses given three weeks apart.
In clinical testing involving some 3,400 adults, the most common side effects included injection-site pain and swelling, muscle aches, headache and fatigue.
More information
To learn more about bird flu, visit flu.gov.
Related Articles
Search Allergy Articles
Is It Allergies or Sinusitis? Many Folks Are Misdiagnosed
Spring Allergies Have Wide-Ranging Effects
Is a Gluten-Free Diet Right for You?
Stay Independent of Allergies, Asthma This July Fourth
Planning Safe Summer Camp Fun for Kids With Allergies & Asthma
Could Inhaling a Statin Help Ease Asthma, COPD?
For Kids in Poorer Neighborhoods, a Move Can Ease Asthma
Canadian Wildfire Smoke's Health Impact on NYC Residents May Have Been Less Than Feared
Roadside Trees, Bushes Are Cutting Air Pollution, Study Finds
Does Your Child Have Asthma? Here's How to Prepare Them to Go Back to School